Acipimox (sodium)
Product Specifications
UNSPSC Description
Acipimox (K-9321) sodium, a nicotinic acid analogue, is an antilipolytic compound. Acipimox sodium stimulates leptin releas, inhibits lipolysis and suppresses systemic levels of free fatty acids (FFAs) and improves insulin sensitivity[1][2][3].
Target Antigen
Others
Type
Reference compound
Related Pathways
Others
Applications
Metabolism-sugar/lipid metabolism
Field of Research
Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/acipimox-sodium.html
Solubility
10 mM in DMSO
Smiles
O=C(C1=C[N+]([O-])=C(C)C=N1)O[Na]
Molecular Weight
176.11
References & Citations
[1]Vestergaard ET, et, al. Short-term acipimox treatment is associated with decreased cardiac parasympathetic modulation. Br J Clin Pharmacol. 2017 Dec;83(12):2671-2677.|[2]Wang-Fisher YL, et, al. Acipimox stimulates leptin production from isolated rat adipocytes. J Endocrinol. 2002 Aug;174(2):267-72.|[3]Ahrén B. Reducing plasma free fatty acids by acipimox improves glucose tolerance in high-fat fed mice. Acta Physiol Scand. 2001 Feb;171(2):161-7.
Shipping Conditions
Room temperature
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-B0283A/Acipimox-sodium-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-B0283A/
Clinical Information
Launched
CAS Number
76958-97-9
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
PA1865-Dylight488 100 μg
Anti-Transcription factor Sp4 Antibody Picoband® (Dylight488 Conjugate)
Ask
View Details 